This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ProtAffin AG (developing therapeutics for cancer and inflammatory conditions) has raised €14.1mm ($18.4mm) through its Series B venture round. New investors Atlas Venture and SR One Ltd. co-led and were joined by current backers Aescap Venture, Entrepreneurs Fund, and Z-Cube. Atlas and SR One will each gain representation on the board. The proceeds will be used to finish preclinical studies and Phase I trials of PA401, ProtAffin's lead drug candidate for chronic and acute inflammation.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?